ライフサイエンスコーパス: cancer survivor

1 ildhood and early-adolescent and young adult cancer survivors.

2 e implications for exercise interventions in cancer survivors.

3 e, 76 years; 62% women; 21% black), 19% were cancer survivors.

4 hronic medical conditions occur in childhood cancer survivors.

5 bute to reduced quality of life in childhood cancer survivors.

6 nsplantation is uncommon in ageing childhood cancer survivors.

7 rm the reproductive counseling of female AYA cancer survivors.

8 nce (FCR) is a common problem experienced by cancer survivors.

9 hildhood, adolescent, and young adult (CAYA) cancer survivors.

10 rsonalized care in limiting neurotoxicity in cancer survivors.

11 s also were greater among HCT versus non-HCT cancer survivors.

12 y in U-shaped pattern among long-term breast cancer survivors.

13 ed with morbidity and functional problems in cancer survivors.

14 n male pubertal, adolescent, and young adult cancer survivors.

15 to enhance evidence-based care for male CAYA cancer survivors.

16 ly affect reproductive outcomes among female cancer survivors.

17 gher (or lower) than average risk for breast cancer survivors.

18 fibrosis and reduce the quality of life for cancer survivors.

19 gnitive impairment is reported frequently by cancer survivors.

20 lp to preserve long-term health of pediatric cancer survivors.

21 ated with late morbidity and mortality among cancer survivors.

22 t in the effect of cardiovascular disease on cancer survivors.

23 thy (CIPN) is a major cause of disability in cancer survivors.

24 ng the functional impact of CIPN symptoms on cancer survivors.

25 o meet the demand of an increasing number of cancer survivors.

26 significantly increasing quality of life for cancer survivors.

27 ny of the CVRFs increased the risk of CVD in cancer survivors.

28 ies investigating chronic pain management in cancer survivors.

29 dimensional digital mammography among breast cancer survivors.

30 vidence-based weight management programs for cancer survivors.

31 ascular homeostasis and long-term effects on cancer survivors.

32 etes, dyslipidemia) on long-term CVD risk in cancer survivors.

33 ase inhibitor (AI) use on CVD risk in breast cancer survivors.

34 and severely impact auditory sensitivity in cancer survivors.

35 is a significant late effect among childhood cancer survivors.

36 as resulted in a growing number of pediatric cancer survivors.

37 ong complications, particularly in pediatric cancer survivors.

38 commendation for HPV vaccination among young cancer survivors.

39 ndations for HPV vaccination among all young cancer survivors.

40 nt tumor cells in breast cancer patients and cancer survivors.

41 evalence of dietary supplement use in breast cancer survivors.

42 and young adult survivors than for childhood cancer survivors.

43 but can cause functional deficits in breast cancer survivors.

44 k of SN when compared with non-NF1 childhood cancer survivors.

45 xicity surveillance recommendations for CAYA cancer survivors.

46 ists in the care of patients with cancer and cancer survivors.

47 nition, mood, and social competence in young cancer survivors.

48 urce of morbidity and mortality among breast cancer survivors.

49 or concern affecting the quality of life for cancer survivors.

50 CT when assessing VAT area and volume among cancer survivors.

51 ospitalization compared with matched non-HCT cancer survivors (280 v 173 episodes per 1,000 person-ye

52 Most childhood cancer survivors (61.9%) perceived themselves at increas

53 Methods Participants included 982 cancer survivors (9 to 26 years of age; 1 to 5 years pos

54 oss intervention for African American breast cancer survivors (AABCS) on weight, body composition, an

55 verse health status outcomes among childhood cancer survivors across 3 decades.

56 verse health status outcomes among childhood cancer survivors across 3 decades.

57 that aim to integrate PCPs into the care of cancer survivors across different settings.

58 Native T1 and ECV remained elevated in cancer survivors after accounting for demographics (incl

59 terial financial hardship was more common in cancer survivors age 18 to 64 years than in those >/= 65

60 In adjusted analyses, cancer survivors age 18 to 64 years who were younger, fe

61 thods A secondary data analysis of 512 women cancer survivors (age, 62 +/- 6 years; time since diagno

62 Cancer survivors ages 9-26 years and 1-5 years off thera

63 rom June 1, 2010, to January 22, 2013, using cancer survivors, ages 7 to 17 years, who were previousl

64 .5 h admissions, 58 healthy women (38 breast cancer survivors and 20 demographically similar controls

65 .7-4.8] for early adolescent and young adult cancer survivors and 5.6 [4.9-6.3] for childhood cancer

66 After exclusions, 108 215 cancer survivors and 523 541 controls were included in t

67 morbidity development over time among breast cancer survivors and a noncancer control group.

68 e and birth between childhood and adolescent cancer survivors and an age-matched comparison group.

69 ise intolerance is prevalent among childhood cancer survivors and associated with all-cause mortality

70 Early-adolescent and young adult cancer survivors and childhood cancer survivors were bot

71 Cancer survivors and comparisons were followed up for ho

72 of obesity increased from 22.4% to 31.7% in cancer survivors and from 20.9% to 29.5% in adults witho

73 equent, late side effects of radiotherapy in cancer survivors and have a detrimental impact on their

74 significant effect on the severity of FCR in cancer survivors and is a promising new treatment approa

75 Colorectal and breast cancer survivors and non-Hispanic blacks were identified

76 significant weight loss in African American cancer survivors and of maintaining weight loss in any c

77 Interviews were limited to older breast cancer survivors and staff at 1 institution.

78 se of a remarkable increase in the number of cancer survivors and the proliferation of new cancer the

79 und surveillance mammography in older breast cancer survivors and to consider cessation while taking

80 and quality of life vs usual care in breast cancer survivors and to determine if changes were sustai

81 examine the evidence of accelerated aging in cancer survivors and to determine the responsible mechan

82 referred treatment for diabetes among breast cancer survivors and whether it benefits breast cancer p

83 er survivors and 5.6 [4.9-6.3] for childhood cancer survivors), and at increased risk of developing g

84 den were colorectal cancer survivors, breast cancer survivors, and non-Hispanic blacks.

85 er primary tumors are not usually present in cancer survivors, and the behavioral consequences of the

86 Childhood cancer survivors are at elevated risk for requiring HAD,

87 Purpose Cancer survivors are at high risk for human papillomavir

88 Young cancer survivors are at increased risk for morbidities r

89 Patients with cancer and cancer survivors are at increased risk of vascular disea

90 iched diets to improve outcomes for prostate cancer survivors are based on expert opinion, preclinica

91 Conclusion HPV vaccine initiation rates in cancer survivors are low.

92 Breast cancer survivors are more likely to develop mood disorde

93 o the heart, such that increasing numbers of cancer survivors are now living with the potentially let

94 cess of basic and disease-specific research, cancer survivors are one of the largest growing subsets

95 aging biomarkers of interstitial fibrosis in cancer survivors are related to prior receipt of a poten

96 portant complication that affects testicular cancer survivors as a consequence of treatment.

97 proximately 25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc., and was available o

98 Methods: Data were tabulated from a Thyroid Cancer Survivors' Association, Inc., survey emailed to a

99 birth outcomes of adolescent and young adult cancer survivors (AYA [diagnosed at ages 15-39 years]) w

100 al symptoms and quality of life among breast cancer survivors (BCSs) who completed treatment.

101 ality of life (secondary outcomes) in breast cancer survivors (BCSs) with a DSM-IV diagnosis of a sex

102 udy, screening mammograms obtained in breast cancer survivors before and after DBT implementation wer

103 of increasing obesity burden were colorectal cancer survivors, breast cancer survivors, and non-Hispa

104 3-5 chronic health conditions than childhood cancer survivors, by comparison with siblings of the sam

105 Low testosterone in cancer survivors can be due to orchidectomy or effects o

106 Childhood cancer survivors carry a high burden of treatment-relate

107 Between 10% and 20% of childhood cancer survivors (CCS) experience impaired growth, leadi

108 ransferase (ALT) level among adult childhood cancer survivors (CCS).

109 Purpose Childhood cancer survivors (CCSs) are at increased risk for subseq

110 ause of morbidity and mortality in childhood cancer survivors (CCSs).

111 Among three large populations of older cancer survivors, chronic opioid use varied by cancer.

112 nt, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monit

113 lowing studies: A Population-Based Childhood Cancer Survivors Cohort Study in Utah, Comparative Effec

114 , obesity increased more rapidly among adult cancer survivors compared with the general population.

115 ore successful chemotherapies, the number of cancer survivors continues to increase.

116 therapies and tumor resection as well as to cancer survivors could eliminate relapse causing dormant

117 apy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate

118 Background Among breast cancer survivors, detecting a breast cancer when it is a

119 spective, multicenter cohort study of 5-year cancer survivors diagnosed before age 21 years from pedi

120 obability of having a first live birth among cancer survivors diagnosed during childhood or adolescen

121 gistry (CCR) was used to identify female AYA cancer survivors diagnosed from January 2000 to December

122 Ninety-two childhood cancer survivors died, 49 as a result of breast cancer.

123 In this Series paper, we define the term cancer survivor, discuss survivors' ongoing needs and pr

124 Breast cancer survivors display altered inflammatory responses

125 nknown whether DXA is comparable to CT among cancer survivors, especially in cases where VAT assessme

126 Cancer survivors, especially the working-age population,

127 tudy is a prospective cohort study of breast cancer survivors established in 2006.

128 date), chronic use among colorectal and lung cancer survivors exceeded chronic use among controls (co

129 With the number of cancer survivors expanding quickly, the time has come fo

130 By and large, NHB and Hispanic childhood cancer survivors experience a comparable burden of morbi

131 Conclusion Childhood cancer survivors exposed to CRT and subsequently diagnos

132 Despite childhood cancer survivors' exposure to various factors that compr

133 Cancer survivors face a variety of challenges as they co

134 of the brain, heart, and joints of pediatric cancer survivors for chemotherapy-induced injuries in on

135 conversations regarding weight management in cancer survivors, fostering a robust research agenda, an

136 rsus 1,541 non-NF1-affected 5-year childhood cancer survivors from the Childhood Cancer Survivor Stud

137 Follow-up of adult-onset cancer survivors given cisplatin should include routine

138 vivors and of maintaining weight loss in any cancer survivor group.

139 Among cancer survivors >/= 65 years of age, those who were you

140 Childhood cancer survivors (>= 5 years since diagnosis), treated b

141 Conversely, prostate cancer survivors had a lower CVD risk (IRR, 0.89; P < .0

142 Births to AYA cancer survivors had a significantly increased prevalenc

143 Eight of 10 cancer survivors had abnormal findings on brain, heart,

144 Early-adolescent and young adult cancer survivors had higher risks of mortality and sever

145 However, early-adolescent and young adult cancer survivors had lower non-recurrent, health-related

146 Overall, cancer survivors had more than two-fold risk of developi

147 Cancer survivors had significant barriers to care and sh

148 Both HCT and non-HCT cancer survivors had significantly greater 10-year cumul

149 Cancer survivors had significantly higher odds of elevat

150 Cancer survivors had significantly higher odds of elevat

151 Over time, breast cancer survivors had significantly higher tumor necrosis

152 Methotrexate-treated cancer survivors had significantly lower cerebral blood

153 essment of Leydig cell function in childhood cancer survivors has been limited.

154 Although the number of cancer survivors has increased substantially in the past

155 cer therapy on health status among childhood cancer survivors has not been evaluated.

156 cer therapy on health status among childhood cancer survivors has not been evaluated.

157 of hospitalization in this specific group of cancer survivors has not been thoroughly evaluated.

158 limited observational evidence suggests that cancer survivors have a decreased risk of developing Alz

159 diac morbidity and mortality among childhood cancer survivors have been described previously.

160 Young male cancer survivors have lower testosterone levels, higher

161 t of potential adverse effects could improve cancer survivors' health and quality of life.

162 udy explores associations between colorectal cancer survivors' healthcare experiences and quality of

163 apping characteristics are elevated in adult cancer survivors; however, it remains unknown whether th

164 tality was modestly elevated among childhood cancer survivors (HR, 1.3; 95% CI, 0.9 to 2.0), survivor

165 ormancy in healthy individuals as well as in cancer survivors; (ii) cancer metastasis could be an ear

166 on CVD in a cohort of postmenopausal breast cancer survivors in analyses that accounted for major CV

167 vance the integration of PCPs in the care of cancer survivors in diverse clinical settings.

168 use of supplements in postmenopausal breast cancer survivors in Germany and investigated association

169 e sub-ethnic groups of Asian American breast cancer survivors in order to propose future directions f

170 distress, and inflammatory biomarkers among cancer survivors in PR.

171 Conclusion Cancer survivors in the United States reported medicatio

172 ion-based data to estimate the percentage of cancer survivors in the United States reporting current

173 is a well-documented complication of breast cancer survivors in the US.

174 Most of the prostate cancer survivors in this study were married (54.3%), wer

175 ns in survivors of DLBCL compared with other cancer survivors, including significantly and consistent

176 ement in self-reported cognitive function in cancer survivors, indicating that this intervention is a

177 The rate of cardiovascular disease among cancer survivors is higher than in the general populatio

178 sk for subsequent breast cancer in childhood cancer survivors is hypothesized to be mediated by TP53

179 ognitive so-called late effects in childhood cancer survivors is possible.

180 nce, in managing all areas of care for adult cancer survivors, is variable with deficits in important

181 e of Medicine report: From cancer patient to cancer survivor: lost in transition, in 2005, there has

182 te of Medicine Report From Cancer Patient to Cancer Survivor: Lost in Transition.

183 Cancer survivors may be at increased risk for opioid-rel

184 Live births to AYA cancer survivors may have an increased risk of preterm b

185 imaging data acquired from 62 primary breast cancer survivors (mean [SD] age, 54.7 [8.5] years) who w

186 Overall, 2598 births to AYA cancer survivors (mean [SD] maternal age, 31 [5] years)

187 .9 (95% CI 5.5-6.2) and among 5804 childhood cancer survivors (median age 34 years; 27-42), it was 6.

188 Cancer survivors might have an excess risk of cardiovasc

189 Among cancer survivors, mortality risk by CVD status was exami

190 otoxicity in a cohort of long-term childhood cancer survivors (N = 108) who received anthracyclines a

191 view Survey, years 2010 to 2013, identifying cancer survivors (n = 3,184) and adults with no history

192 Cancer survivors (n = 50) and non-cancer participants (n

193 zed crossover trial, 51 women (n = 32 breast cancer survivors, n = 19 noncancer controls; mean +/- SD

194 and a main cause of sensory disturbances in cancer survivors, negatively impacting patients' quality

195 Among this cohort, we identified 41 matched cancer survivors/non-cancer participants pairs.

196 lap between these diseases, with millions of cancer survivors now at risk of developing CVD.

197 Childhood cancer survivors of African ancestry are at higher risk

198 In this study, childhood cancer survivors of African ancestry exposed to cardioto

199 g data from 167 nonirradiated male childhood cancer survivors of European ancestry from the St.

200 to 2.93) when compared with patients without cancer; survivors of leukemia and breast cancer were at

201 nd 18 months after primary cancer treatment (cancer survivors) or within a comparable time frame (con

202 compared with 2.9% in the non-NF1 childhood cancer survivors (P = .003), yielding a 2.4-fold higher

203 y/diagnosis have substantially increased the cancer survivor population, although many survivors repo

204 Weight loss interventions among breast cancer survivors positively affect weight, behavior, bio

205 Moreover, being a cancer survivor, predicted more barriers to receiving he

206 d the 10 earlier randomized trials in female cancer survivors provide support for the feasibility of

207 it is reasonable to propose that we are all cancer survivors rather than cancer-free individuals bec

208 Colorectal cancer survivors relied on oncology professionals for ca

209 Childhood cancer survivors reported a higher prevalence of frailty

210 target that can preserve bone and improve a cancer survivor's quality of life.

211 Conclusion Among breast cancer survivors, screening with digital breast tomosynt

212 Cancer survivors seek the resumption of a normal and hea

213 sight) and compared it with standard care in cancer survivors self-reporting cognitive symptoms.

214 If health care providers are to transform cancer survivor services then investment is required in

215 This study of over 200 000 cancer survivors shows that age at cancer diagnosis was

216 ffects of cancer therapy) than did childhood cancer survivors (SMR 4.8 [95% CI 4.4-5.1] vs 6.8 [6.2-7

217 was used to evaluate the association between cancer survivor status and risk of developing each comor

218 S and Canadian participants in the Childhood Cancer Survivor Study (CCSS) cohort and validated in the

219 The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort o

220 The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort s

221 ts and Methods Participants in the Childhood Cancer Survivor Study (CCSS; n = 13,060) were observed t

222 ears old, from 1970 to 1999 in the Childhood Cancer Survivor Study (median age at diagnosis, 7.0 year

223 h conditions were evaluated in the Childhood Cancer Survivor Study among 5-year survivors of medullob

224 hildhood cancer survivors from the Childhood Cancer Survivor Study and 176 nonoverlapping NF1-affecte

225 The Teenage and Young Adult Cancer Survivor Study cohort comprises 200 945 5-year su

226 ality among 34,033 patients in the Childhood Cancer Survivor Study cohort who survived at least 5 yea

227 In the Childhood Cancer Survivor Study cohort, the 20-year cumulative inc

228 osed between 1970 and 1986, in the Childhood Cancer Survivor Study cohort.

229 urvivors and 2,146 siblings in the Childhood Cancer Survivor Study completed a survey ascertaining ad

230 ndent cohort of survivors from the Childhood Cancer Survivor Study corroborated the overall limited g

231 The Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 20

232 The British Childhood Cancer Survivor Study is a population-based cohort of 34

233 tcomes in aging survivors from the Childhood Cancer Survivor Study on the basis of therapeutic exposu

234 d for symptom domains by using the Childhood Cancer Survivor Study sibling cohort.

235 ndred four female survivors in the Childhood Cancer Survivor Study who were treated with chest radiot

236 lation-based TYACSS (Teenage and Young Adult Cancer Survivor Study) (N=178,962) was linked to Hospita

237 Female participants in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of c

238 Data from the Childhood Cancer Survivor Study, a cohort of survivors of at least

239 21 survivors exposed to CRT in the Childhood Cancer Survivor Study, a diagnosis of meningioma and ons

240 utcomes after LMB treatment in the Childhood Cancer Survivor Study.

241 son group who were enrolled in the Childhood Cancer Survivor Study.

242 thin the recently extended British Childhood Cancer Survivor Study.

243 are, among a low-income population of breast cancer survivors (survivors).

244 adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide a

245 sult of any cause was higher among childhood cancer survivors than among controls (HR, 2.2; 95% CI, 1

246 after breast cancer was higher in childhood cancer survivors than in women with de novo breast cance

247 Cancer survivors that were affected by HM reported incre

248 For almost all cancer survivors, the risk of fatal heart disease increa

249 For almost all cancers survivors, the risk of stroke increases with tim

250 quences of cancer diagnosis and treatment in cancer survivors to enhance an integrated cancer service

251 The French CCS Study holds data on 7,670 cancer survivors treated before 2001.

252 Childhood cancer survivors treated with chemotherapy only, particu

253 y, longitudinal reports of SNHL in childhood cancer survivors treated with contemporary RT are limite

254 hildhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head

255 One hundred Gastrointestinal and pancreatic cancer survivors underwent abdominal and pelvis CT and w

256 diagnosis (as applicable) to non-HCT 2-year cancer survivors, using the state cancer registry (n = 5

257 initiation rates were significantly lower in cancer survivors versus the general population (23.8%; 9

258 the prevalence of HPV vaccine initiation in cancer survivors versus the US population and examined p

259 cumulative incidence of SNs in NF1 childhood cancer survivors was 7.3%, compared with 2.9% in the non

260 Chronic use among breast cancer survivors was less than that of controls each yea

261 fruit and vegetable consumption among breast cancer survivors was not associated with breast cancer-s

262 To assess the risk of ESKD among childhood cancer survivors, we conducted a nationwide, population-

263 d young adult cancer survivors and childhood cancer survivors were both at greater risk of developing

264 Rates of medication use in cancer survivors were compared with rates in the general

265 The fractions of long-term cancer survivors were estimated to be 47.4% and 18.0% in

266 Overall, 2782 cancer survivors were hospitalized for a cerebrovascular

267 pared with adults with no history of cancer, cancer survivors were significantly more likely to repor

268 1), indicating that an estimated 2.5 million cancer survivors were taking medication for anxiety or d

269 Medically fragile populations, such as cancer survivors, were significantly affected.

270 rs, we identified 53,032 hospitalizations in cancer survivors, whereas 38,423 were expected, resultin

271 d PDGF-AA, were significantly upregulated in cancer survivors while MMP9 and Osteopontin both had sig

272 n primary care providers (PCPs) as receiving cancer survivors who are transferred after successful tr

273 improvement in therapies, the population of cancer survivors who can expect to live for 5 or more ye

274 study from April to July 2016, 10 pediatric cancer survivors who completed chemotherapy underwent im

275 The number of cancer survivors who develop new cancers is projected to

276 erall survival was significantly worse among cancer survivors who developed CVD (60%) when compared w

277 Cancer survivors who developed CVD had an 11-fold increa

278 e important implications because identifying cancer survivors who have elevated CVD risk is of paramo

279 ad not yet initiated their treatment, and 54 cancer survivors who received either anthracycline-based

280 Cancer survivors who were uninsured, had lower family in

281 For breast cancer survivors who wish to conceive, the risk of death

282 A total of 556 prostate cancer survivors who, more than 1 year after treatment,

283 Approximately 4% to 5% of breast cancer survivors will develop a new ipsilateral or contr

284 One hundred breast cancer survivors with a body mass index >/= 25 kg/m(2) w

285 Patients and Methods We recruited adult cancer survivors with a primary malignancy (excluding ce

286 Conclusion Many (57%) older breast cancer survivors with an estimated short life expectancy

287 association study was conducted in childhood cancer survivors with and without cardiomyopathy (cases

288 tion, gait patterns, and falls between women cancer survivors with and without symptoms of CIPN to id

289 al of testosterone replacement in young male cancer survivors with borderline low testosterone (7-12

290 are have resulted in a growing population of cancer survivors with comorbid, chronic health condition

291 This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score

292 Childhood cancer survivors with hypertension after anthracycline e

293 ual surveillance mammography in older breast cancer survivors with limited life expectancy are not kn

294 Pediatric cancer survivors with low BMD may benefit from low-magni

295 In young male cancer survivors with low-normal morning total serum tes

296 on should be considered for 5-year childhood cancer survivors with severe end-organ failure.

297 and health-related quality of life in breast cancer survivors with treatment-induced menopausal sympt

298 Cancer survivors with two or more CVRFs had the highest

299 provide coordinated, comprehensive care for cancer survivors, with an emphasis on the role of primar

300 s who developed CVD (60%) when compared with cancer survivors without CVD (81%; P < .01).